PRINCETON, N.J., June 16, 2020 /PRNewswire/ — Quartesian, a multinational Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, today announced

Princeton, NJ – May 27, 2020 – Quartesian, a multinational Clinical Research Organization (CRO) serving the biopharmaceutical and medical device

Prediction: In 10 years, clinical trials will be nearly paperless. And clinical trial historians will note that the Coronavirus pandemic

With increasing drug development costs and complexity, meaningful clinical partnerships can help sponsors establish their most efficient and cost-effective processes.

The start of the new year brought some changes for the FDA and EMA. In an effort to keep you

March 18, 2020 Hello Everyone,  This is to inform you that Quartesian is closely tracking the Coronavirus (COVID-19) pandemic outbreak

Throughout 2019, Quartesian continues to gain momentum with strong uptake rates for new services and large contract growth. With over

Quartesian is excited to announce a new offering: a suite of clinical trial data pharmacovigilance services. Our services for clinical

Quartesian has entered a multi-year agreement with Medrio, a leading eClinical technology provider, to provide even more high-quality data to

Quartesian, a leading data CRO quickly becoming a clinical data services industry favorite, recently announced a second consecutive year of

In exciting news for Quartesian and their clients, an agreement with Medidata will now provide complete access to the unified Medidata

If you take a look at the most recent issue of Pharma Tech Outlook, you’ll see a familiar face on the